Insider trade

Director purchased ~$100K of BSX shares in the open market

Traded May 20, 2026 · Filed May 21, 2026

~$100K
Reported value · 1,770 sh @ $56.49: 1,770
Holds after · shares reported: -23.7%
stock since the trade · S&P 500 +3.1%, $56.67 → $43.23 on Oct 1

Why it stands out

A board member of Boston Scientific spent $100K of their very own money to buy Boston Scientific shares. 2 other people at Boston Scientific bought some too, in the same month.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: May 20, 2026
Reporting period: Not applicable
Filed with the SEC: May 21, 2026

Director$25K–$100K3 insiders bought in 30d

Context

Classification

open market purchase

Code P — open-market or private purchase

Absolute commitment

~$99,987

Shares × reported transaction price

Size band

$25K–$100K

Rarity

Not enough history to judge

Confirmed open-market purchases by the same insider in the available history

Cluster activity

3 distinct insiders in 30 days

Distinct insiders at the same issuer with confirmed open-market purchases

Timing vs results

28 days after results of Apr 22, 2026, 70 days before results of Jul 29, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $56.67 on May 20, 2026, 8% above its 52-week low and 48% below its high, after a 9% drop over the previous 30 trading days

52-week range $52.68 (May 15, 2026) to $108.14 (Sep 8, 2025), 7% of the way up, from 251 adjusted closes. 30 trading days earlier: $62.56 on Apr 8, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Mar 5, 2026 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.

2 such cases were open. In re: Boston Scientific Corporation Securities Litigation, docket 1:26-cv-40075, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	-16.4%	+1.4%	-17.8%
30 days	-23.3%	-0.2%	-23.1%
90 days	-14.6%	+2.3%	-16.8%

Past results only. Not a forecast.

Source receipt

Record ID: 0001225208-26-005548
Filed / recorded: May 21, 2026, 9:21 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: BOSTON SCIENTIFIC CORP
Issuer CIK: 885725
Ticker: BSX
Reporting person: Cheryl Pegus
Relationship: Director
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: May 20, 2026
Transaction code: P
Shares / units: 1,770
Price per share: $56.49
Acquired / disposed: Acquired (A)
Shares owned after: 1,770
Ownership form: Direct
Amendment: No

Footnotes from the filing

Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $56.49 to $56.5009, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.